Mantrax Ventures,TCGLS collaborate for dev solutions

“TCGLS assists partner companies to expand and strengthen product pipelines. The in-house expertise,track-record and unique integrated research platform significantly lowers up-front and ongoing costs of research and development,” said Dr Kapil Talwar,Director,Mantrax Ventures.

TCGLS,as part of the New York based The Chatterjee Group (TCG),has trust based relationships with over 200 clients including 15 out of the top 20 global pharmaceutical companies. Pfizer recently entered into a collaborative discovery agreement with TCGLS for developing a portfolio of pre-clinical candidate molecules.

“Our talented scientists and state-of-the-art research facilities enable us to engage seamlessly with our partners to accelerate and enhance the drug development process securely under one roof,” said Swapan Bhattacharya,Managing Director,TCG Lifesciences.

“We want to dedicate ourselves to helping unlock the vast potential of intellectual property assets which exist at Australian life science companies. Our flexible engagement models help in creating a win-win situation across stakeholders. A large benefit of our outsourcing model is that our partners are serviced by a dedicated project team and all intellectual property generated is owned by them,” he added.

The global outsourcing services range from pre-clinical candidate nomination to clinical trials management and synthesis of cGMP drug substances. Capabilities are maintained within leading technology park facilities and are maintained by over 1,000 scientists and professionals with EU and US experience.